It is well known that hepatitis C virus (HCV) is the main causative agent of chronic hepatitis, and about 50%-70% of HCV acute infections develop into chronic hepatitis, of which 10%-20% of chronic carriers eventually develop into chronic cirrhosis or liver cancer. Moreover, the only treatment for chronic hepatitis C is interferon combined with ribavirin for antiviral therapy. In principle, elderly patients should also be treated with antiviral therapy, but in the past, in view of the fact that elderly patients with hepatitis C generally have underlying disease and the adverse effects of antiviral therapy, the uncertainty of efficacy, and the assessment of the benefits and risks of treatment, antiviral therapy is not advocated for elderly patients, but only passive liver-protective and enzyme-lowering therapy, which increases the proportion of cirrhosis and hepatocellular carcinoma in patients of these ages and seriously This has increased the rate of cirrhosis and hepatocellular carcinoma in patients of these ages, seriously affecting the quality of life of elderly patients in their later years and reducing their well-being. Therefore, I successfully cured an 80-year-old man with hepatitis C cirrhosis by using PELANEN (long-acting interferon) in a small dose and long course of treatment.